Characterization of DLBCL samples
| Tumor cell characteristics . | Response to the XIAP antagonist . | P . | |
|---|---|---|---|
| LD50 less than 39 μM . | LD50 39 μM or more . | ||
| Apoptosis profile* | .02 | ||
| Low | 1 | 7 | — |
| High | 9 | 3 | — |
| GCB or ABC phenotype† | NS | ||
| GCB | 4 | 7 | — |
| ABC | 5 | 3 | — |
| NI | 1 | 0 | — |
| Tumor cell characteristics . | Response to the XIAP antagonist . | P . | |
|---|---|---|---|
| LD50 less than 39 μM . | LD50 39 μM or more . | ||
| Apoptosis profile* | .02 | ||
| Low | 1 | 7 | — |
| High | 9 | 3 | — |
| GCB or ABC phenotype† | NS | ||
| GCB | 4 | 7 | — |
| ABC | 5 | 3 | — |
| NI | 1 | 0 | — |
DLBCL samples were divided into 2 groups based on the median LD50 dose of 39 μM after 4 hours of incubation with the XIAP antagonist 1396-12.
NS indicates not significant; NI, not interpretable; and —, not applicable.
Indicates expression levels of proapoptotic genes (including MCL1-short, Bax-Long, Bax-short, BCL-Rambo, BCL-G, Noxa, Bad, Bak, Bim, Bid, Harakiri, PUMA, Bik, BNIP3, BNIP3L, MAP1, BMF, AIF, Apaf-1, Apaf-1L, Apaf-1XL and Smac) and antiapoptotic genes (including: BCL-W, BCL-XL, BCL-2, BCL2-A1, Appolon, BIRC7, MCL1-long, NIAP, cIAP, cIAP2, XIAP, Survivin, c-Flip and Pi-9) as described previously.9
According to the previously described algorithm.29